Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
Year: 2026
Type: erratum
Abstract: In the version of this article initially published, there was an error in Table 1 where the PROMIS Fatigue median for the total population, now reading “55.1” appeared originally as “51.1.” In addition, errors in Supplementary Table 2 values have now been updated as follows: Eosinophil count median + Benralizumab (n = 67 ) has been changed from 1,070.0 (230–5,620) to 1,085.0 (360–5,620); Eosinophil count median + Total ( N = 133) has been changed from 1,120.0 (60–20,910) to 1,100.0 (60–20,910); and Prior HES-related biologic therapy in the past 12 months for Omalizumab + Benralizumab ( n = 67) has been changed from 2 (1.5%) to 2 (3.0%). The tables have been updated in the HTML and PDF versions of the article.
Source: Nature Medicine
Authors: Princess U. Ogbogu, Florence Roufosse, Praveen Akuthota, Piotr Kuna, Matthieu Groh, Andreas Reiter, Akira Yokota, Salman H. Siddiqui, Pim G. N. J. Mutsaers, Bing Li, Paneez Khoury, Lila M. Bahadori, Artur Bednarczyk, Gerben Bouma, Laura G. Brooks, Jorge Ferreira, Hanna Grindebacke, Calvin N. Ho, Priya Jain, Rebecca L. Palmer, Maria L. Jison, Amy D. Klion, on behalf of NATRON study group
Institutions: Rainbow Babies & Children's Hospital, Case Western Reserve University, Université Libre de Bruxelles, Erasmus Hospital, University of California San Diego, Medical University of Lodz, Université de Versailles Saint-Quentin-en-Yvelines, Hôpital Foch, Heidelberg University, University Medical Centre Mannheim, Chiba Aoba Municipal Hospital, Royal Brompton Hospital, NIHR Imperial Biomedical Research Centre, Imperial College London, Erasmus MC, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, National Institutes of Health, National Institute of Allergy and Infectious Diseases, AstraZeneca (United States), AstraZeneca (Poland), AstraZeneca (United Kingdom), AstraZeneca (Sweden)
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
OpenAlex ID: W7160280485